Clene shares surge 12.19% after-hours after JonesTrading and Benchmark reiterate Buy ratings with $30–$31 price targets following positive CNM-Au8 biomarker data analysis.

Clene (NASDAQ: CLNN) surged 12.19% in after-hours trading following a series of bullish analyst actions and positive clinical data. JonesTrading reiterated a "Buy" rating with a $30 price target, while Benchmark reaffirmed a "Buy" recommendation and $31 target, citing statistically significant reductions in neurodegenerative biomarkers (NfL and GFAP) for its ALS drug CNM-Au8. These updates align with Clene’s recent announcement of a planned Type C FDA meeting in Q1 2026 to discuss accelerated approval pathways for CNM-Au8, reinforcing optimism about regulatory progress. The stock’s sharp rise reflects investor confidence in the drug’s potential for accelerated approval and the credibility of analysts with strong track records, including Justin Walsh (4-star analyst) and Benchmark’s endorsement of the therapy’s disease-modifying capabilities.